Press release
Esophageal Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in Esophageal Cancer Research. Learn more about our innovative pipeline today! @ Esophageal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Esophageal Cancer Pipeline Report
* On 20 August 2025, Merck Sharp & Dohme LLC announced the initiation of a Phase 1/2, multicenter, open-label umbrella platform study designed to assess the safety and tolerability of sacituzumab tirumotecan in combination with pembrolizumab and fluoropyrimidine chemotherapy. The trial focuses on first-line (1L) treatment for patients with locally advanced unresectable or metastatic HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma.
* On 20 August 2025, Hoffmann-La Roche initiated a clinical study aimed at evaluating the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC). This regimen is being compared against a control arm of atezolizumab-matching placebo plus tiragolumab-matching placebo with PC as a first-line treatment for participants with unresectable locally advanced, unresectable recurrent, or metastatic esophageal carcinoma (EC).
* DelveInsight's Esophageal Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Esophageal Cancer treatment.
* The leading Esophageal Cancer Companies such as OncoTherapy Science, Inc./Shionogi & Co., Oncolys BioPharma Inc, Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu HengRui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, Suzhou Zelgen Biopharmaceuticals, Active Biotech/NeoTX Therapeutics, Rakuten Medical, HLB, CDR-Life, Schrodinger, BioSyngen, Guangzhou Bio-gene Technology, GO Therapeutics and others. .
* Promising Esophageal Cancer Therapies such as Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.
Stay informed about the cutting-edge advancements in Esophageal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Esophageal Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Cancer Emerging Drugs Profile
* S-588410: OncoTherapy Science, Inc. /Shionogi & Co.
S-588410 is cancer peptide vaccine licensed out from OncoTherapy to Shionogi & Co., Ltd. It is a subunit vaccine commercialized by Shionogi. It is administered subcutaneously as an emulsion. The therapeutic candidate is a mixed peptide-cocktail vaccine of S-288310 and S-488410 comprising of five human leukocyte antigens (HLA)-A 2402-restricted epitope peptides derived from oncoantigen. The drug candidate is a new molecular entity. Currently, the drug is in the Phase III stage of its development for the treatment of Esophageal Cancer.
* Telomelysin: Oncolys BioPharma Inc
Telomelysin (OBP-301) is a gene-modified oncolytic adenovirus in which selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. From the result of Phase I clinical study in the US, Telomelysin showed abscopal effect, which non-injected tumor as well as injected tumor was regressed in melanoma patients after single injection into one single tumor and found that not only increasing infiltration of CD8 and antigen presenting cells but diminishing Treg cells in injected tumor site. In preclinical studies for Telomelysin, Oncolys has demonstrated effective anti-tumor activity on various cancer cells, and there was no finding that may bring safety concerns in toxicological studies as well as bio-distribution study. Currently, the drug is in the Phase II stage of its development for the treatment of Esophageal Cancer.
* LVGN-6051: Lyvgen Biopharma
LVGN6051 is xLinkAb anti-4-1BB (CD137) agonist mAb that has been designed to activate 4-1BB optimally in tumor microenvironment by targeting both 4-1BB and FcRIIB. LVGN6051 strikes a balance between antitumor efficacy and safety by agonizing 4-1BB only in the presence of FcRIIB, which is expressed on immune cells enriched in the tumor microenvironment, including B cells, dendritic cells and granulocytes. Currently, the drug is in the Phase I stage of its development for the treatment of Esophageal Cancer.
* AN-0025: Adlai Nortye Biopharma
AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist, discovered by Eisai Co., Ltd. (Eisai), and designed to modulate the tumor microenvironment. Adlai Nortye has been granted exclusive rights concerning the research, development, manufacture and marketing in all regions outside of Japan and part of Asia (excluding China) by Eisai. It is currently under development for the treatment of locally advanced rectal cancer with radiation therapy in the ongoing global Phase II ARTEMIS study. We presented Phase 1b results for this indication at the European Society for Medical Oncology ("ESMO") in October 2019, where combination therapy with AN0025 and RT/CRT was safe and enabled 36% of patients to achieve either a cCR or pathologic complete response (pCR). Currently, the drug is in the Phase I stage of its development for the treatment of Esophageal Cancer.
The Esophageal Cancer pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
* Esophageal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.
Get a detailed analysis of the latest innovations in the Esophageal Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Esophageal Cancer Unmet Needs [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Cancer Companies
OncoTherapy Science, Inc./Shionogi & Co., Oncolys BioPharma Inc, Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu HengRui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, Suzhou Zelgen Biopharmaceuticals, Active Biotech/NeoTX Therapeutics, Rakuten Medical, HLB, CDR-Life, Schrodinger, BioSyngen, Guangzhou Bio-gene Technology, GO Therapeutics and others.
Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Download DelveInsight's latest report to gain strategic insights into upcoming Esophageal Cancer Therapies and key Esophageal Cancer Developments @ Esophageal Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Esophageal Cancer Pipeline Report
* Coverage- Global
* Esophageal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Esophageal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc ., and others.
* Esophageal Cancer Therapies- Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.
Which companies are leading the race in Esophageal Cancer drug development? Find out in DelveInsight's exclusive Pipeline Report-access it now! @ Esophageal Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Esophageal Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Esophageal Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* S-588410: OncoTherapy Science, Inc. /Shionogi & Co.
* Mid Stage Products (Phase II)
* Telomelysin: Oncolys BioPharma Inc
* Early Stage Products (Phase I)
* LVGN-6051: Lyvgen Biopharma
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Esophageal Cancer Key Companies
* Esophageal Cancer Key Products
* Esophageal Cancer- Unmet Needs
* Esophageal Cancer- Market Drivers and Barriers
* Esophageal Cancer- Future Perspectives and Conclusion
* Esophageal Cancer Analyst Views
* Esophageal Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Esophageal Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4152933 • Views: …
More Releases from ABNewswire
Holiday Skin Stress? KREMOLOGIE Trademark Offers Professional Solutions for Sens …
Professional-grade skincare brand KREMOLOGIE addresses the seasonal skin challenges facing women this holiday season. With formulations rooted in clinical esthetics expertise, the brand provides barrier-strengthening solutions for reactive skin stressed by holiday demands, travel, and harsh winter conditions.
The holiday season brings joy, celebration, and unfortunately for many women, significant skin stress. Between November and January, dermatologists and estheticians report increased consultations for dehydration, sensitivity flare-ups, and accelerated aging signs. KREMOLOGIE…
Jupiter Landscaping Boosts Home Values in Boynton Beach With High End Landscape …
Jupiter Landscaping enhances Boynton Beach homes with luxury landscape designs, boosting curb appeal and property value.
Boynton Beach, FL - Landscaping experts in Boynton Beach are making a significant impact on home values with their top-tier landscape designs. Specializing in custom landscaping solutions, these professionals offer comprehensive services that enhance curb appeal, create functional outdoor spaces, and increase property value, especially for homeowners seeking Boynton Beach landscaping [https://www.jupiterlandscaping.net/boynton-beach-fl].
"We believe that landscaping…
Naples Comfort Systems Delivers Emergency AC Installation Solutions to Protect G …
Naples Comfort Systems provides fast emergency AC installation to keep Golden Gate families safe and cool during extreme heat.
Naples, FL - In response to the sweltering temperatures affecting Golden Gate and surrounding areas, Naples Comfort Systems is offering AC Installation Golden Gate FL [https://stahlmanac.com/air-conditioning/golden-gate-fl/] services on an emergency basis to help protect local families from the dangers of extreme heat. As the summer heat intensifies, the company is stepping up…
Emergency AC Repair Support Expanded in Golden Gate as Heat Intensifies
Emergency AC repair services in Golden Gate expand as rising temperatures increase demand for fast, reliable cooling solutions.
Naples, FL - As temperatures in Golden Gate and surrounding areas rise to extreme levels, homeowners and businesses are facing the critical need for reliable air conditioning services. To meet this growing demand, Naples Comfort Systems is significantly boosting its emergency AC Repair Golden Gate FL [https://stahlmanac.com/air-conditioning/golden-gate-fl/], ensuring that residents and businesses stay…
More Releases for Esophageal
Rising Prevalence Of Chronic Esophageal Disorders Boosts The Esophageal Catheter …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Esophageal Catheters Market Size By 2025?
The market for esophageal catheters has experienced significant expansion recently. Its growth is projected to continue from a market size of $2.43 billion in 2024 to an increased value of $2.64 billion in 2025, reflecting a compound annual growth…
Evolving Market Trends In The Esophageal Dilator Industry: Advanced Solutions En …
The Esophageal Dilator Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Esophageal Dilator Market Size During the Forecast Period?
The esophageal dilator market size will grow from $1.49 billion in 2024 to $1.57 billion in 2025 at a CAGR of 5.2%. Growth…
Evolving Market Trends In The Esophageal Dysphagia Industry: Innovative Technolo …
The Esophageal Dysphagia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Esophageal Dysphagia Market Size During the Forecast Period?
The market size for esophageal dysphagia has seen robust growth in the past few years. Projections show that it is set to expand…
Key Trend Reshaping the Esophageal Dilator Market in 2025: Advanced Solutions En …
What combination of drivers is leading to accelerated growth in the esophageal dilator market?
The esophageal dilator market is expected to see growth driven by the increasing occurrence of esophageal disorders. These disorders refer to a range of conditions affecting the esophagus, responsible for transporting food and fluids from the mouth to the stomach. The escalated prevalence of such disorders can be linked to factors such as the growing instances of…
Advanced Solutions Enhanced Esophageal Dilator Market Trend: A Crucial Influence …
What Is the Expected Size and Growth Rate of the Esophageal Dilator Market?
The market size for esophageal dilators has experienced robust growth in the past few years. The market's value, estimated at $1.49 billion in 2024, is predicted to inflate to $1.57 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.2%. This positive trend during the historical period is primarily driven by factors such as an increase…
Top Factor Driving Esophageal Catheters Market Growth in 2025: Rising Prevalence …
How Big Is the Esophageal Catheters Market Expected to Be, and What Will Its Growth Rate Be?
The esophageal catheters market has experienced significant growth in recent years. It will grow from $2.43 billion in 2024 to $2.64 billion in 2025, at a CAGR of 8.6%. The growth can be attributed to advancements in critical care, the rise of cardiac and respiratory disorders, the use of minimally invasive procedures, and developments…
